Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:09 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 9,942 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

NCT00000868
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 3, 2026, 8:09 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Project ECHO in Nursing Homes

NCT04499391
View directory record Official record
Conditions
Covid19
Interventions
Project ECHO
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Nov 3, 2026, 8:09 PM EST
Completed Phase 4 Interventional Results available

Valganciclovir to Reduce T Cell Activation in HIV Infection

NCT00264290
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus Infections
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Nov 3, 2026, 8:09 PM EST
Completed No phase listed Observational

Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy

NCT00915213
View directory record Official record
Conditions
Bacterial Infection
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Irvine, California • Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Nov 3, 2026, 8:09 PM EST
Active, not recruiting Not applicable Interventional

Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients

NCT05688423
View directory record Official record
Conditions
Injection Site Infection, Substance Use Disorders
Interventions
SIRI Team, Treatment as Usual
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Nov 3, 2026, 8:09 PM EST
Completed Not applicable Interventional

A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.

NCT00000855
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 5 Days
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 3, 2026, 8:09 PM EST
Withdrawn Phase 2 Interventional

Garlic in Hyperlipidemia Caused by HAART

NCT00029250
View directory record Official record
Conditions
HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Hyperglycemia
Interventions
Garlic powder standardized to allicin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Nov 3, 2026, 8:09 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Text Message Study

NCT01789697
View directory record Official record
Conditions
Anxiety, Pain, Surgical Site Infection
Interventions
cellular device/computers
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Nov 3, 2026, 8:09 PM EST
Recruiting No phase listed Observational

Detection and Characterization of Infections and Infection Susceptibility

NCT00404560
View directory record Official record
Conditions
Immune Deficiencies
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 8:09 PM EST
Terminated Phase 4 Interventional Results available

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

NCT00488059
View directory record Official record
Conditions
HIV Infections
Interventions
enfuvirtide [Fuzeon], Optimized background ARV, Integrase inhibitor
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Hobson City, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Nov 3, 2026, 8:09 PM EST
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Nov 3, 2026, 8:09 PM EST
Completed Phase 4 Interventional Results available

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

NCT00158860
View directory record Official record
Conditions
Herpes Genitalis
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Nov 3, 2026, 8:09 PM EST
Completed Not applicable Interventional Results available

Improving Quality of Life for Veterans Undergoing Interferon Treatment

NCT00117559
View directory record Official record
Conditions
Depression, Hepatitis C
Interventions
Telehealth Treatment
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Nov 3, 2026, 8:09 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Homologous Re-infection With Dengue 1 or Dengue 3

NCT05967455
View directory record Official record
Conditions
Dengue
Interventions
Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC), Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Nov 3, 2026, 8:09 PM EST
Completed Phase 2 Interventional

A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3

NCT00000625
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Nov 3, 2026, 8:09 PM EST
Completed No phase listed Observational

Determining the Etiology of Febrile Neutropenia Using the Karius Sequencing-based Infectious Disease Diagnostic Assay

NCT02912117
View directory record Official record
Conditions
Infection, Neutropenia
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Nov 3, 2026, 8:09 PM EST
Completed Phase 1 Interventional

Combination Drug Treatment of Pediatric HIV Infection

NCT00001818
View directory record Official record
Conditions
HIV Infection
Interventions
Hydroxyurea
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 8:09 PM EST
Completed Not applicable Interventional

Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE)

NCT04350723
View directory record Official record
Conditions
Corona Virus Infection, Covid19, COVID-19
Interventions
Awake Proning
Procedure
Lead sponsor
St. Joseph's Healthcare Hamilton
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Nov 3, 2026, 8:09 PM EST
Recruiting Not applicable Interventional

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

NCT06263426
View directory record Official record
Conditions
Hiv
Interventions
HIV D-/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 3, 2026, 8:09 PM EST
Completed Phase 1 Interventional

Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients

NCT04199715
View directory record Official record
Conditions
Hepatitis B
Interventions
Heplisav-B
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Nov 3, 2026, 8:09 PM EST
Not listed Phase 1 Interventional

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

NCT03588715
View directory record Official record
Conditions
HIV, HIV/AIDS, HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
Drug
Lead sponsor
Luis Montaner
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Nov 3, 2026, 8:09 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

NCT04486625
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Aztreonam-Avibactam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Nov 3, 2026, 8:09 PM EST
Recruiting Phase 4 Interventional

Decolonization to Reduce After-Surgery Events of Surgical Site Infection

NCT05586776
View directory record Official record
Conditions
Surgical Site Infection
Interventions
4% Chlorhexidine Gluconate, 2% Mupirocin, Soap Without Antiseptic Properties (Placebo), Placebo Nasal Ointment
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
2,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Orange, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 3, 2026, 8:09 PM EST
Completed Phase 1 Interventional

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

NCT00000768
View directory record Official record
Conditions
Colitis, HIV Infections
Interventions
Glutamic acid hydrochloride, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 3, 2026, 8:09 PM EST